Search hospitals > North Carolina > Chapel Hill
Unc Aids Crs
Claim this profileChapel Hill, North Carolina 27514
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Infections
Conducts research for HIV
Conducts research for Contagious Diseases
Conducts research for AIDS
105 reported clinical trials
1 medical researcher
Summary
Unc Aids Crs is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of Human Immunodeficiency Virus Infection, Infections, HIV, Contagious Diseases, AIDS and other specialties. Unc Aids Crs is involved with conducting 105 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as David A. Wohl, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global LeaderHBeAg positive
HBeAg negative
HIV-1 positive
2Infections
Global LeaderTop PIs
Clinical Trials running at Unc Aids Crs
Human Immunodeficiency Virus Infection
HIV
Obesity
HIV/AIDS
Contagious Diseases
HIV Infection
Infections
AIDS
Hepatitis A
Chronic Hepatitis B
Doravirine
for HIV-Associated Weight Gain
This trial is testing if changing HIV medications to doravirine or switching drug combinations can help patients who have gained weight on their current treatment. The study focuses on people with HIV who have experienced significant weight gain. Doravirine works by blocking a different part of the virus, which might help reduce weight gain and improve overall health. Doravirine is an alternative treatment option for individuals who do not tolerate efavirenz.
Recruiting3 awards Phase 410 criteria
IL-15 Superagonist + Antibodies
for HIV/AIDS
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Recruiting1 award Phase 116 criteria
Monoclonal Antibodies + ART
for HIV Infection
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks compared to participants who receive placebo plus ART. * Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Unc Aids Crs?
Unc Aids Crs is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of Human Immunodeficiency Virus Infection, Infections, HIV, Contagious Diseases, AIDS and other specialties. Unc Aids Crs is involved with conducting 105 clinical trials across 53 conditions. There are 1 research doctors associated with this hospital, such as David A. Wohl, MD.